WORLD'S LARGEST DRUG-ELUTING STENT REGISTRY REACHES HALFWAY POINT

Boston Scientific announced that enrollment has exceeded 13,000 patients in the TAXUS OLYMPIA registry, designed to confirm the safety and performance of the Company's second-generation drug-eluting coronary stent (DES), TAXUS Liberte, in a real-world setting. OLYMPIA is the world's largest DES registry to date and plans to enroll up to 27,000 patients treated for complex coronary lesions, at more than 500 centers worldwide.
CNW Telbec